Satellos Bioscience Inc (MSCLF)

[Letterpenny]

Daniel Teper is looking for a Opthamology company to merge with. I see Daniel going full circle to acquire his Bertiliumumab eye indication for peanuts. Monetization is a great idea for Satellos. Good idea Gleeson. lol. I like how majority of shares are being held in escrow 36 months from last share deal with Bloom. That’s a nice way to freeze a company in its place. So many irons in the fire. Hula Hula Cuckoo Penny

[Letterpenny]

I see merger coming in 2024. I like Naya Biosciences as the potential merger candidate. Hula Hula Cuckoo Penny

[AJ Freely]

$MSCLF - Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
👉Current Price $0.32

[Dapper1]

Cash raised will keep the lights on for a while, not sure if this will be a winner being run by Canucks, time will tell.

[Oloo]

50m cash raised. Something brewing!

[Oloo]

News on the go !

[Oloo]

On the way for a lead candidate:

https://ca.finance.yahoo.com/news/satellos-bioscience-inc-cso-present-110000839.html

Buckle Up!

[Oloo]

Awesome thing coming soon !

[Renee]

Effective Dec. 10,2021 ICOTF will change to MSCLF.

***Note: The letter F on the symbol denotes a Foreign stock.

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Renee]

As soon as FINRA posts the official ticker change to MSCL I will submit the change to Admin. Thanks for the heads-up.

[Dapper1]

New ticker - MSCL - I use TD Ameritrade and I don't see my shares in my account anymore, probably going to take the transfer agent 3-5 days to get everything switched over.

[Renee]

ICOTF: effective Aug. 18,2021 Ico Therapeutics Inc. will change to Satellos Bioscience Inc. and a one for one for 20 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[Dapper1]

Newsfile Corp.
Thu, July 8, 2021, 5:11 PM
--------
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") is pleased to announce that the Company has received formal conditional approval from the TSX Venture Exchange (the "Exchange") of iCo's proposed business combination (the "Transaction") with Satellos Bioscience Inc. ("Satellos").

The Company has filed an information circular on SEDAR (the "Circular") that describes the Transaction in detail and will be mailing the Circular to shareholders on or about July 13, 2021. iCo has set August 3, 2021 as the date of the special meeting of shareholders of the Company to approve the Transaction, in accordance with the rules of the Exchange. The shareholder meeting is more fully described in the Circular.

In connection with the Transaction, iCo previously announced, on April 27, 2021, the successful closing of a private placement (the "Financing") of 85,294,117 subscription receipts (the "Subscription Receipts") at a price of $0.085 per Subscription Receipt for aggregate gross proceeds of approximately C$7.25 million, conditional upon successful closing of the Transaction. The Subscription Receipts will convert into common shares of iCo following the satisfaction of the escrow release conditions attached to the Subscription Receipts.
--------
Finally, iCo announces that if the Transaction is approved by iCo and Satellos shareholders, the Company expects trading of the shares of the combined company to begin trading on the Exchange as Satellos Bioscience Inc. under the symbol MSCL during the week of August 9, 2021.

[Oloo]

Wait for the next press release. We will see what is the vibe.

[boston79]

Voting No on this deal is crucial. Ico is worth more than this startup

[boston79]

Easy $1.00 that’s only $152 million market cap, only at a pathetic 17 million dollar market cap currently.

[J_Dean]

Hello. What’s everyone’s price per share target here, short term and long term? Seems to be great potential here with what’s in their pipeline. Let’s hope the market thinks so too and sends this over $1.00 a share. Potential merger/buyout? Opinions? Thank you

[boston79]

CB-DT run imminent. Ico is a covid play now- minimum 150 million -300 million market cap

[boston79]

https://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2020;volume=15;issue=3;spage=118;epage=124;aulast=AL-Khikani

Here’s why ico is heading to dollar land

[boston79]

Someone’s front loading milllions of shares. Could be a big win once peeps realize we are a covid play with 12 million dollar market cap currently

[boston79]

Ya it’s a covid play now. This stock is going to dollars

[Oloo]

Something going on!

[Mikefbi]

It's here WoW

[boston79]

“Acceleration event” in the dec 1. Filing indicates they plan on being taken over. Load up easy 10 + bagger

[boston79]

Big move coming $$$$$

[kratz]

Mike what are thinking about this stock and what do u see happening in the near term bin worried.....Alexion isn’t saying anything and I hope they don’t leave ICo high n dry. They need money soon.

[kratz]

I agree.....now when should we hear something positive from Alexion n how they will move Bertilimumab forward..... any clue

[Mikefbi]

Real partners
Real value
Slowly and surely this imo will be a winner .
More transparency

[kratz]

Why

[Mikefbi]

I believe this is a long term winner
Long a very bullish

[Mikefbi]

Still believe it's a great long term investment
Very Long
Still Buying

[Jabramowitz]

iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo 019) Update / Appointment of Kishor Wasan as Director of Research
8:01 am ET April 15, 2020 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") announced today the successful results of a Phase 1b clinical study of iCo's Oral Amphotericen B Delivery System ("Amp B" or "iCo 019") which began on December 9, 2019. The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of 100mg and 400mg doses of iCo 019.

iCo also announced the appointment of Dr. Kishor Wasan as Director of Research for the Company. Dr. Wasan has received numerous awards for his contributions to health sciences including the Canadian Society of Pharmaceutical Sciences Leadership award for outstanding contributions to Pharmaceutical Sciences in Canada and is a Fellow of the Canadian Academy of Health Sciences and the American Association of Pharmaceutical Scientists. Dr. Wasan has published over 240 peer-reviewed articles and 280 abstracts in the area of lipid-based drug delivery and lipoprotein-drug interactions. Most recently, Dr. Wasan served as the Dean of the College of Pharmacy and Nutrition of the University of Saskatchewan from August 2014 to June 2019. Dr. Wasan led the research team at the Wasan lab at the University of British Columbia that developed what has become iCo 019, and will initially focus his efforts on the further development of iCo 019 via partnerships and collaborations. "We are delighted to have Kish formally onboard leading our research efforts. We've worked with him since the founding of the Company and will benefit from his proven research abilities and deep connectivity to the global pharmaceutical industry," noted William Jarosz, the CEO of iCo.

Commenting on the iCo 019 trial Dr. Wasan noted, "In the Phase Ib human clinical study all repeated doses of ICO-019 were well tolerated with no serious adverse events including no signs of GI, kidney or liver toxicities. ICO-019 at the 100 mg dose achieved a median plasma Cmax of 25 ng AmB/mL and AUC (0-inf) 990 hr* ng/mL after day 1 of dosing and a median plasma Cmax of 44 ng AmB/mL and AUC (0-inf) 1998 hr*ng/mL after 10 day of dosing. This approximate doubling of the AUC (0-inf) measure between day 1 and day 10 was observed not only at the 100 mg dose but at the 400 mg dose as well.

These data suggest that we may have developed a novel oral amphotericin B formulation that is safe and tolerable following multiple dosing to healthy human subjects. In addition, the increased AUC observed in the phase 1b human clinical studies between the day 1 of dosing to the day 10 of dosing suggests that iCO-19 formulation has the ability to increase and sustain Amphotericin B tissue concentrations within infected tissues without the associated GI, liver or kidney toxicity. I am pleased with the PK results from the Phase 1b trial."

In addition, iCo announced it will delay the start of the anticipated Phase 2 trial of iCo 019 as the result of uncertainty generated by the current COVID-19 events. "We are concerned that the ongoing pandemic could cause clinical challenges affecting our trial's timeline, leading to longer than expected delays and higher costs. Despite the positive findings of our Phase 1b trial, we believe it is the best use of our resources, and the resouces of our clinical research partners in the current environment, to delay the start of the Phase 2 trial until we have more clarity regarding the course of COVID-19 and its effect on clinical trial practices," stated Mr Jarosz.

[Jabramowitz]

Alexion is obligated to pay them $32m to move Bert to ph3...a 10x move on their current market cap to about 20c per share plus

[BrianSkidless]

Still believe it might and should benefit from IMNP demise? What's your target?

[Jabramowitz]

yes sir

[BrianSkidless]

You're still holding this?

[Jabramowitz]

iCo Therapeutics Announces Completion of Phase 1b Oral Amphotericin B Study Dosing and Follow Up
8:02 am ET February 10, 2020 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in its Phase 1b study have received doses of Oral Amphotericin B (either 100mg and 400mg/day) over ten days and, subsequent to dosing, have been followed up for an additional ten days. Full results of the Phase 1b study are currently expected before the end of Q1 2020.

Stated Dr. Peter Hnik, Chief Medical Officer of iCo, "Results from the Phase 1b study using multiple ascending doses of oral Amphotericin B will provide additional safety and pharmacokinetic information needed for the upcoming Phase 2 clinical study in patients with vulvovaginal candidiasis ("VVC").

According to Denning et al, "Worldwide, recurrent vulvovaginal candidiasis affects about 138 million women annually (range 103-172 million), with a global annual prevalence of 3871 per 100?000 women; 372 million women are affected by recurrent vulvovaginal candidiasis over their lifetime. The 25-34 year age group has the highest prevalence (9%). By 2030, the population of women with recurrent vulvovaginal candidiasis each year is estimated to increase to almost 158 million, resulting in 20,240,664 extra cases with current trends using base case estimates in parallel with an estimated growth in females from 3·34 billion to 4·181 billion. In high-income countries, the economic burden from lost productivity could be up to US$14·39 billion annually."*

A Phase 2 study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis is currently expected to commence in Q2 2020.

A number of additional indications, that may also be difficult and impractical to treat using intravenous formulation, are expected to be explored (active treatment and prevention) in the near future.

iCo also announces that the Company has also engaged Proconsul Capital ("Proconsul") for investor relations activities. Proconsul will be paid $8,000 CDN, excluding taxes, on a month-to-month basis.

[Jabramowitz]

from Alexion website:

Immune Pharma - anti-eotaxin-1 antibody
Phase: Preclinical


In November 2019, Alexion acquired an anti-eotaxin-1 antibody from Immune Pharma for potential development in inflammatory diseases.

[Jabramowitz]

some folks on the IMNP chat room still believe that Bert has not been transferred to Alexion...dummies

[Jabramowitz]

they were chasing some shares on Tuesday the last trading day of the year but quiet today starting out in 2020...but yes this one should do well with Alexion as the new partner to develop Bertilimumab that IMNP dropped the ball on it.

[Mikefbi]

Should be a very good investment
Long term

Long and Happy

[Jabramowitz]

iCo Therapeutics Announces Completion of Sub-license Transfer and Full Dosing of Fifty Per Cent of Phase 1b Subjects
8:03 am ET December 24, 2019 (Newsfile) Print
Vancouver, British Columbia--(Newsfile Corp. - December 24, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received 100 mg doses of Oral Amphotericin B on a daily basis over ten days, with no drug-related adverse events observed to date. One additional cohort is expected to be dosed in early Q1 2020, followed by the initiation of a Phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis in Q2 2020.

iCo also announces the completion of the transfer of its sub-license of iCo-008, an antibody targeting eotaxin-1, with the receipt of an assignment and assumption acknowledgement from its new biotechnology partner with a market capitalization in excess of $24 billion USD. Furthermore, iCo has communicated to its pharmaceutical partner, which previously licensed iCo-008 worldwide exclusive to iCo, the completion of said sub-license transfer in its annual report.

[Jabramowitz]

Phase 2 Bertilimumab Trial
On May 15, 2018 our licensee announced positive Phase 2 data for the treatment of moderate-to-extensive bullous pemphigoid. iCo Therapeutics is eligible to receive up to $32M in potential future milestone payments. For more information please refer to:
www.immunepharma.com/immune-pharmaceuticals-presents-updated-positive-results-from-phase-2-trial-of-bertilimumab-in-bullous-pemphigoid/

ALEXION PHARMACEUTICALS TOOK OVER THIS LICENSE FROM IMNP BANKRUPTCY

[Jabramowitz]

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced it has engaged Ora, Inc., the world's leading full-service ophthalmic CRO and product development firm, to assist the Company with its ophthalmic regulatory and development strategy for iCo-008. It is expected that this work will ultimately result in a meeting with the FDA prior to initiation of a Phase 2 trial. Ora has vast expertise in ocular allergy and immunology, both pre-clinical and clinical, and has been involved in multiple drug approvals in this area. Paul Gomes, Vice President of Allergy and Blepharitis at Ora, commented, "We are very excited to collaborate with iCo in engaging with the FDA to establish a development pathway for iCo-008 for severe ocular allergic diseases. In the US, there have been no new therapies approved for these orphan diseases within the last 25 years. Innovation is necessary to increase the available treatment options and to reduce or eliminate the need for chronic steroid usage. "

Previously iCo announced the conclusion of court proceedings in the US and Israel, resulting in approval of Alexion's asset purchase agreement related to iCo-008, an anti-eotaxin-1 antibody. iCo retains worldwide ophthalmic use indications, including Vernal Keratoconjunctivitis (VKC) and Atopic Keratoconjunctivitis (AKC).

[Jabramowitz]

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that all subjects in the first of two cohorts in its Phase 1b study have received the first dose of Oral Amphotericin B. Dosing will occur over a period of ten days. One additional cohort is expected to be dosed in Q1 2020, followed by the initiation of a Phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study in vulvovaginal candidiasis in Q2 2020.

All subjects in the Phase 1b study will be dosed for 10 consecutive days with additional 10 days of follow-up (for a total of 20 days). Two doses of oral Amphotericin B (100mg and 400mg), showing promising pharmacokinetic outcomes in the previous Phase 1 trial (using a single dose only), will be used in the Phase 1b study. Extensive safety and pharmacokinetic testing will also be performed throughout the study to indicate which dose might be the safest and effective for future trials in patients with fungal diseases.

[Mikefbi]

Continue to buy for the long term

[Mikefbi]

Looking good continue to buy based on their new partnership.
Nice long term investment IMO

[whytestocks]

News: $ICOTF iCo Therapeutics Announces Third Quarter 2019 Financial Results

Vancouver, British Columbia--(Newsfile Corp. - December 2, 2019) - iCo Therapeutics  (TSXV: ICO) (OTCQB: ICOTF)  ("iCo" or the "Company"), today reported financial results for the Quarter ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dolla...

Find out more ICOTF - iCo Therapeutics Announces Third Quarter 2019 Financial Results

[tmeier]

What's the deal here?

[Nostockdamus26]

Solid investment right here..when people find this, it will explode!